Monte Rosa Therapeutics
GLUE
53 hedge funds and large institutions have $742M invested in Monte Rosa Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 11 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 10
2.9% more ownership
Funds ownership: 75.23% → 78.13% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less capital invested
Capital invested by funds: $759M → $742M (-$17.4M)
5% less funds holding
Funds holding: 56 → 53 (-3)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.9M |
| 2 |
BlackRock
New York
|
+$5.97M |
| 3 |
Jennison Associates
New York
|
+$4.89M |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$1.96M |
| 5 |
E
Ergoteles
New York
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.91M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.67M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.09M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.8M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$1.11M |
GLUE Hedge Fund Activity: Q4 2021 in Review
53 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q4 2021, worth a combined $742M — down 2.3% from $759M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GLUE and 9 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 24 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $20.9M. The largest seller was Millennium Management, exiting entirely with an estimated $3.91M sold.
- 53 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q4 2021, down from 56 in Q3 2021.
- Funds reported $742M of Monte Rosa Therapeutics stock for Q4 2021, down 2.3% quarter-over-quarter.
- 9 funds opened new Monte Rosa Therapeutics positions in Q4 2021 and 11 closed out, a net change of -2 holders.
- The largest Monte Rosa Therapeutics buyer in Q4 2021 was T. Rowe Price Associates, an estimated $20.9M added.
- The largest Monte Rosa Therapeutics seller in Q4 2021 was Millennium Management, an estimated $3.91M sold.
Based on aggregated 13F filings for Q4 2021.